Navigation Links
Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Date:9/16/2011

DURHAM, N.C., Sept. 16, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that investigators will present preliminary data for CMX001 in a late-breaker presentation at the 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, Chicago – September 17-20).  

Genovefa Papanicolaou, M.D., Associate Member of Infectious Diseases Service at Memorial Sloan-Kettering Cancer Center and one of the lead investigators in Chimerix's ongoing Phase 2 cytomegalovirus (CMV) study, will give a presentation entitled, "CMX001 is not nephrotoxic or myelosuppressive in 183 patients with life threatening dsDNA infections including refractory Cytomegalovirus, Adenovirus, and BK Virus," on Sunday, September 18 at 8:30 am CDT.  Immediately following Dr. Papanicolaou's presentation, Richard Whitley, M.D., Distinguished Professor at The University of Alabama at Birmingham, will present "New Antivirals for Herpes Viruses: What Can We Look Forward to and When?," which highlights CMX001. Both presentations are part of the "Herpes and Other Viruses" slide session that begins at 8:30 am CDT.  In accordance with ICAAC embargo policy, these data remain under embargo until conclusion of the late-breaker session on Sunday, September 18 at 11:00 am CDT.  

Data from Dr. Papanicolaou's presentation was generated as part of Chimerix's expanded access program, through which Chimerix has dosed over 300 subjects with CMX001 since March 2009, including 183 subjects under investigator-held Emergency Investigational New Drug applications (EINDs) or foreign equivalents at over 80 medical centers in the United States, Canada, Europe, and Israel.  Through EINDs, CMX001 has been used for the treatment of a wide range of life-threatening infections caused by dsDNA viruses, including CMV, adenovirus (AdV), BK virus (BKV), Epstein Barr virus (EBV), herpes simplex v
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... from MedImmune, PRINCETON, N.J., Aug. 12 ... its partner MedImmune, Inc. has,initiated a Phase 2A ... of systemic lupus erythematosus (SLE or lupus).,MEDI-545 is ... Human,Antibody Development System(R). Under the terms of the ...
... Therapeutics, Inc., a,privately held immunotherapeutics discovery and ... of novel immunotherapies for the,treatment of cancer, ... agreements with the Memorial Sloan-Kettering Cancer Center,s,Sloan-Kettering ... http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ), The first license ...
Cached Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
(Date:4/17/2014)... -- The world is less than 40 years away ... for people and governments, according to a top scientist ... first time in human history, food production will be ... land, water and energy," said Dr. Fred Davies, senior ... "Food issues could become as politically destabilizing by 2050 ...
(Date:4/17/2014)... 17, 2014While 94 per cent of Canadians surveyed said ... newborns for a specific number of genetic conditions, only ... participate in screening that would sequence their newborns, genomes.,Most ... in their first day or two of life in ... their heels and tested for about five to 54 ...
(Date:4/17/2014)... Vice-Chancellor, Professor Patrick Johnston, whose work has transformed cancer ... Fellow of the European Academy of Cancer Sciences., The ... advisory body of highly distinguished oncologists and cancer researchers ... by cancer in Europe. , Professor Johnston, whose leadership ... from the bottom of the UK league table to ...
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research ... their annual Founders Dinner for their support of TGen,s ... took place March 28 in Scottsdale. , Catherine Ivy, ... Foundation, received TGen,s John S. McCain Leadership Award, named ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Minn., Sept. 13 Mayo Clinic,s,Multidisciplinary Simulation Center ... in the United States to be accredited by,the ... ACS positions,Mayo to offer and advance medical education ... team members, abilities to keep pace with,rapidly changing ...
... Twins and at Interlachen Country Club ... support for suicide prevention., MINNEAPOLIS, Sept. 13 ... Week,(September 9-15, 2007) this week with a special appearance ... the Hubert H. Humphrey Metrodome in,Minneapolis. SAVE is a ...
... White House Office of National Drug Control Policy to Include ... Ads as Part of New Anti-Methamphetamine Initiative, ... that its award-winning television advertisements have been,selected by the White ... a new national Meth prevention campaign. The Anti-Meth Campaign ...
... Calif., Sept. 13 Delphon Industries, based in,Hayward, ... its UltraTape division.,UltraTape Industries, of Salem, Oregon, is ... Delphon acquired UltraTape Industries on,June 20, 2007 to ... to provide unique materials and services to high ...
... Everett,s body temperature helped protect his spinal cord, doctors ... Buffalo Bills football player Kevin Everett was being rushed ... life-threatening spinal cord injury, he was already getting experimental ... Everett,s spinal cord was damaged in his neck as ...
... Goes Beyond Just Vitamins to Provide a Supplement for ... Joint Health, Company ... ... Joint Juice, Inc., the creator,of the original ready-to-drink glucosamine supplement, announced the launch,of the ...
Cached Medicine News:Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 2Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 3Health News:SAVE Recognizes National Suicide Prevention Week 2Health News:Meth Project Advertisements Selected for National Prevention Campaign 2Health News:Meth Project Advertisements Selected for National Prevention Campaign 3Health News:Novel Cooling Therapy May Have Aided Injured Football Player 2Health News:Novel Cooling Therapy May Have Aided Injured Football Player 3Health News:Novel Cooling Therapy May Have Aided Injured Football Player 4Health News:Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide 2
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Inquire...
... BT table comes in two modelsthe BT4, ... the BT5, which offers five. With the ... adjust to suit your needs. Both ... controls, side rails, ankle/foot supports, adjustable arm ...
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures....
Medicine Products: